ReviewJournal of clinical medicine2014
Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice.
Review in Journal of clinical medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation.Scientific reports · 2024Pooled it
- Quercetin-loaded PCL scaffold suppresses bone metastatic tumors and augments in situ bone formation.BMC biotechnology · 2026Article
- Advanced models of lobular breast cancer metastasis capture clinical organ tropism, endocrine response, and bone remodeling.bioRxiv : the preprint server for biology · 2026Article
- Extracellular vesicle-mediated preconditioning of osteoblasts by ER+ breast cancer cells: implications for the bone metastatic niche.Frontiers in pharmacology · 2026Article
- Antiresorptive agents in the management of bone metastatic disease: a multicenter mixed-methods study in Palestinian clinical practice.BMC cancer · 2025Article
- Article
- New Radiopharmaceutical Tracers in Breast Cancer Diagnosis and Therapy.Anti-cancer agents in medicinal chemistry · 2025Review
- Concise review: breast cancer stems cells and their role in metastases.Annals of medicine and surgery (2012) · 2024Review
- Clinical practice guidelines for full-cycle standardized management of bone health in breast cancer patients.Cancer innovation · 2024Article
- Unveiling the Link Between Breast Cancer Treatment and Osteoporosis: Implications for Anticancer Therapy and Bone Health.BioMed research international · 2024Review
- Prescription patterns of analgesics in cancer patients with bone metastases in Japan: a retrospective database study.International journal of clinical oncology · 2023Article
- Mechanisms of bone pain: Progress in research from bench to bedside.Bone research · 2022Review
- Neurotropin alleviates rat osteocarcinoma pain via PIranian journal of basic medical sciences · 2021Article
- Bone Metastatic Breast Cancer: Advances in Cell Signaling and Autophagy Related Mechanisms.Cancers · 2021Review
- Functional Genomic Analysis of Breast Cancer Metastasis: Implications for Diagnosis and Therapy.Cancers · 2021Review
- Precise Diagnosis and Therapy of Bone Cancer Using Near-Infrared Lights.Frontiers in bioengineering and biotechnology · 2021Review
- Article
- Article
- Comparison of the clinicopathological characteristics and prognosis between Chinese patients with breast cancer with bone-only and non-bone-only metastasis.Oncology letters · 2020Article
- Role of the bone microenvironment in bone metastasis of malignant tumors - therapeutic implications.Cellular oncology (Dordrecht, Netherlands) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone is the most common site of metastasis from breast cancer. Bone metastases from breast cancer are associated with skeletal-related events (SREs) including pathological fractures, spinal cord compression, surgery and radiotherapy to bone, as well as bone pain and hypercalcemia, leading to impaired mobility and reduced quality of life. Greater understanding of the pathophysiology of bone metastases has led to the discovery and clinical utility of bone-targeted agents such as bisphosphonates and the receptor activator of nuclear factor kappa-B ligand (RANK-L) antibody, denosumab. Both are now a routine part of the treatment of breast cancer bone metastases to reduce SREs. With regards to prevention, there is no evidence that oral bisphosphonates can prevent bone metastases in advanced breast cancer without skeletal involvement. Several phase III clinical trials have evaluated bisphosphonates as adjuvant therapy in early breast cancer to prevent bone metastases. The current published data do not support the routine use of bisphosphonates in unselected patients with early breast cancer for metastasis prevention. However, significant benefit of adjuvant bisphosphonates has been consistently observed in the postmenopausal or ovarian suppression subgroup across multiple clinical trials, which raises the hypothesis that its greatest anti-tumor effect is in a low estrogen microenvironment. An individual patient data meta-analysis will be required to confirm survival benefit in this setting. This review summarizes the key evidence for current clinical practice and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.